These 3 Penny Stocks Have More Upside Than You Think

Penny Stocks Under $5 with Upside Potential

Key Concepts:

• Penny Stocks: Stocks trading under $5, often characterized by higher volatility and risk.
• Analyst Sentiment: Overall opinion of analysts regarding a stock’s future performance, often reflected in price targets.
• Consensus Price Target: The average price target predicted by analysts covering a stock.
• Institutional Ownership: The percentage of a company’s shares held by institutional investors (e.g., mutual funds, hedge funds).
• Adjusted EPS: Earnings Per Share adjusted for one-time items, providing a clearer picture of ongoing profitability.
• GAP Basis: Generally Accepted Accounting Principles – a standard set of accounting rules.
• Clinical Trials (Phases 1-3): Stages of testing for new drugs, progressing from initial safety testing to large-scale efficacy studies.
• FDA Approval: Approval from the Food and Drug Administration required for drugs and vaccines to be marketed in the US.
• Compound Annual Growth Rate (CAGR): The average annual growth rate of an investment over a specified period.

I. Market Overview & Selection Criteria

The discussion centers on identifying three penny stocks (defined as under $5) with significant upside potential in a volatile market. The analyst, Chris Marott, focused on stocks exhibiting positive analyst sentiment and possessing substantial consensus price targets exceeding their current trading prices. He highlighted the rarity of finding penny stocks with sufficient analyst coverage to generate reliable price targets, making this list unique. The overall market volatility is acknowledged as a factor impacting these smaller companies.

II. Grab Holdings (GRAB) – The “Everything App” of Southeast Asia

• Ticker Symbol: GRAB
• Current Price (as of recording): $4.80
• Consensus Price Target: $6.47 (54% upside)
• Business Model: Grab is described as an “everything app” operating in Southeast Asia, encompassing e-commerce, technology, and various services (similar to Uber with added e-commerce functionality).
• Financial Performance: Grab recently achieved profitability for the first time (on an adjusted EPS basis) and also showed profitability on a GAAP basis, albeit smaller. Revenue is increasing year-over-year and sequentially. Q3 2023 revenue was $378 million, slightly missing expectations but still higher year-over-year.
• Analyst Coverage: Covered by seven analysts, which is considered substantial for a company of its size.
• Key Argument: Despite current market pressures, Grab’s profitability, revenue growth, and diversification make it an attractive investment, offering exposure to international markets.
• Notable Quote (Chris Marott): “This is a company that's functioning. It's continuing to grow and it's already getting that revenue coming in. So, an interesting first company to look at.”
• Additional Resource: Thomas Hughes’ analysis of Grab (linked in the video description).

III. Vaxart – Pioneering Oral Vaccines

• Ticker Symbol: VXRT
• Current Price (as of recording): $0.68
• Consensus Price Target: $2.00 (195% upside)
• Business Model: A biotech company focused on developing oral vaccines for influenza, norovirus, and COVID-19. The potential benefits of oral vaccines include eliminating needle fear and potentially eliciting a broader immune response.
• Pipeline: Several drugs are in various stages of clinical trials (Phase 1, 2, and 3).
• Risks: Vaxart is a “true penny stock” with limited analyst coverage (only one analyst providing a price target). Success is heavily dependent on FDA approval, which is uncertain and can take over a year. The stock is prone to volatility due to speculative trading.
• Institutional Ownership: Low institutional ownership (18%), but significant institutional inflows in the past year (10:1 ratio of inflows to outflows).
• Key Argument: The innovative approach of oral vaccines presents a significant opportunity, but investors must be prepared for high risk and potential volatility.
• Notable Quote (Chris Marott): “These are stocks you have to have conviction on if you're going to be investing in them.”
• Caution: Biotech stocks are inherently risky due to the unpredictable nature of clinical trials and FDA approval processes.

IV. ThreadUp – Online Consignment & Thrift Marketplace

• Ticker Symbol: TDUP
• Current Price (as of recording): $4.71
• Consensus Price Target: $12.50 (165% upside)
• Business Model: An online consignment and thrift marketplace targeting millennials and Gen Z, offering secondhand clothing.
• Financial Performance: Revenue has been growing year-over-year (Q3 2023 revenue was $82 million, beating expectations of $77.3 million). The company is nearing profitability, with losses decreasing in recent quarters.
• Analyst Coverage: Covered by six analysts.
• Institutional Ownership: High institutional ownership (89%), suggesting a potential macro-economic influence on the stock price.
• Market Trends: The secondhand market is projected to grow at a 9% CAGR through 2029 (according to Global Data).
• Key Argument: Despite a recent pullback potentially linked to interest rate changes, ThreadUp’s strong growth, analyst optimism, and the expanding secondhand market make it a compelling investment.
• Notable Quote (Chris Marott): “I really think this is an interesting name and all three of these names very interesting concept and unique to see where the price targets are at least on Grab and Thread Up too.”

V. General Considerations & Resources

• Volatility: Penny stocks are inherently volatile and require a long-term investment horizon.
• Due Diligence: Thorough research is crucial before investing in penny stocks.
• MarketBeat Resources:
  • Article on MarketBeat’s top five rated small-cap stocks (QR code and link provided).
  • Thomas Hughes’ analysis of Grab (linked in the video description).
  • Bridget’s Buys – a daily video series tracking stock performance.

Conclusion:

The video presents three penny stocks – Grab, Vaxart, and ThreadUp – each with unique characteristics and potential for significant growth. While acknowledging the inherent risks associated with penny stocks, the analyst highlights positive analyst sentiment, revenue growth, and innovative business models as key factors driving their potential. Investors are advised to conduct thorough research and consider their risk tolerance before investing in these volatile stocks. The emphasis on analyst coverage and consensus price targets provides a data-driven approach to identifying potential opportunities within the penny stock market.